Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of
1934
|
Date of
Report (Date of earliest event reported)
|
June 14, 2018
|
|
SANUWAVE Health, Inc.
|
|
(Exact
name of registrant as specified in its charter)
|
|
Nevada
|
000-52985
|
20-1176000
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
|
3360 Martin Farm Road, Suite 100, Suwanee, Georgia
|
30024
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code
|
(770) 419-7525
|
|
|
|
N/A
|
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registration is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company. ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01
Entry into a Material Definitive Agreement.
On June
26, 2018, SANUWAVE Health, Inc., a Nevada Corporation (the
“Company”), announced that the Company had entered into
an agreement (the “Agreement”) with Johnfk Medical Inc. (“FKS”),
effective as of June 14, 2018, pursuant to which the Company and
FKS will enter into a joint venture for the manufacture, sale and
distribution of the Company’s dermaPACE® and
orthoPACE® devices. The
Agreement provides that the parties will work together to enter
into a definitive agreement over the next five months.
Under
the Agreement, FKS paid the Company an initial distribution rights
fee in Taiwan on June 22, 2018 in the amount of $500,000, with an
additional initial distribution rights fee in Singapore, Malaysia,
Brunie, Cambodia, Myanmar, Laos, Indonesia, Thailand, Philippines
and Vietnam (the “SEA Region”) in the third quarter of
2018 in the amount of $500,000.
The
foregoing description of the Agreement does not purport to be
complete and is subject to, and qualified in its entirety by, the
full text of the Agreement, a copy of which is attached to this
Current Report on Form 8-K as Exhibit 10.1 and is incorporated by
reference herein.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
|
Agreement, dated June 14,
2018, by and among the Company and Johnfk Medical
Inc.
|
|
|
|
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
SANUWAVE
HEALTH, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated:
June 29, 2018
|
By:
|
/s/
Lisa E.
Sundstrom
|
|
|
|
Name:
|
Lisa E.
Sundstrom
|
|
|
|
Title:
|
Controller
and Chief Financial Officer
|
|